Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-01-22
2009-08-11
McIntosh, III, Traviss C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S025000, C514S027000, C514S481000, C514S645000, C514S646000
Reexamination Certificate
active
07572774
ABSTRACT:
The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.
REFERENCES:
patent: 5158976 (1992-10-01), Rosenberg
patent: 5254683 (1993-10-01), Chapdelaine et al.
patent: 5523322 (1996-06-01), Blache et al.
patent: 6384069 (2002-05-01), Feuerstein et al.
patent: 0 146 338 (1985-06-01), None
patent: 0 631 777 (1995-01-01), None
patent: WO98/51291 (1998-11-01), None
Mattei et al., “Naftazone reduces glutamate cerebro spinal fluid levels in rats and glutamate release from mouse cerebellum synoptosomes”, Neuroscience Letters, vol. 271, pp. 183-86, 1999.
Neiva et al., “Aluminum induces lipid peroxidation and aggregation of human blood platelets”, Brazilian Journal of Medical and Biological research, vol. 30, pp. 599-604, 1997.
Neu et al., “Platelet aggregation and multiple sclerosis”, Acta neurol. scandinav., vol. 66, pp. 497-504, 1982.
Lechner et al., “Parkinsons with a high vascular risk - Lechner-Ott Syndrome”, Wiener medizinische Wochenschrift, vol. 136, No. 15-16, pp. 387, 388, 390, and 391, 1986.
Accession No. 97018149: Rao et al., Indian Journal of physiology and pharmacology, (Jan. 1996) vol. 40, No. 1, pp. 5-14.
Accession No. 1998334761: Li et al., American Journal of Alzheimer's Disease, (1998) vol. 13, No. 5, pp. 236-244.
Rao et al., Indian Journal of Physiology and Pharmacology, Jan. 1996, vol. 40, No. 1, pp. 5-14.
Sharma et al., “Platelet Aggregation in Patients with Parkinson's Disease”, Stroke, a Journal of Cerebral Circulation, Dec. 1991, vol. 22, No. 12, 1607-08.
Mattei et al., “Naftazone reduces glutamate cerebro spinal fluid levels in rats and glutamate release from mouse cerebellum synaptosomes,”Neuroscience Letters, 1999, pp. 183-186, vol. 271, Elsevier Science Ireland Ltd., Ireland.
Azza et al., “Lipid Peroxidation and Lysosomal Integrity in Different Inflammatory Models in Rats: The Effects of Indomethacin and Naftazone,”Pharmacological Research, 1995, pp. 279-285, The Italian Pharmacological Society, Italy.
Zicot, “Etude multicentrique de l'efficacite et de la tolerance de la naftazone (Mediaven® 10 MG). Comaparaison de deux schemas posologiques,”Revue Medicale De Liege, Apr., 1993. pp. 224-228, France.
Herber et al., “Reduction and Glucuronidation of Naftazone by Human and Rat Liver Microsomes,”Drug Metabolism and Disposition, 1995, pp. 1305-1314, vol. 23, No. 12, The American Society for Pharmacology and Eperimental Therapeutics, Bethesda, Maryland, USA.
Bloy Christian
Israel Maurice
Mattei Cesar
Molgo Jordi
Buchanan Ingersoll & Rooney P.C.
Centre National de la Recherche Scientific (C.N.R.S.)
McIntosh, III Traviss C
LandOfFree
Methods for treating glutamate cytotoxicity with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating glutamate cytotoxicity with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating glutamate cytotoxicity with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4064318